Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Klinique Medical Clinic PCLBKK:KLINIQ -0.87%90 3-Year EBITDA Growth Rate is 16.60% as of Jun. 2026, which is 8% below its 10-year median of 18.00. GuruFocus rates BKK:KLINIQ with a GF Score™ of 90/100 and a GF Value™ of ฿41.00 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 71 Personal Services companies, The Klinique Medical Clinic PCL ranks better than 54.93% on this metric.
During the past 12 months, The Klinique Medical Clinic PCL's average EBITDA Per Share Growth Rate was 20.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 21.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of The Klinique Medical Clinic PCL was 29.20% per year. The lowest was 16.60% per year. And the median was 18.00% per year.
The Klinique Medical Clinic PCL (BKK:KLINIQ) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
The Klinique Medical Clinic PCL 3-Year EBITDA Growth Rate Related Terms
BKK:KLINIQ vs ROL, SCI, HRB: 3-Year EBITDA Growth Rate Comparison
For the Personal Services subindustry, The Klinique Medical Clinic PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Klinique Medical Clinic PCL 3-Year EBITDA Growth Rate vs Personal Services Industry
For the Personal Services industry and Consumer Cyclical sector, The Klinique Medical Clinic PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where The Klinique Medical Clinic PCL's 3-Year EBITDA Growth Rate falls into.
The Klinique Medical Clinic PCL 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.60% mean?
The Klinique Medical Clinic PCL (BKK:KLINIQ) has a 3-Year EBITDA Growth Rate of 16.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for The Klinique Medical Clinic PCL and its competitors. This is near median its historical median of 18.00. Over the past decade, The Klinique Medical Clinic PCL's 3-Year EBITDA Growth Rate has ranged from 16.60 to 29.20. According to the industry distribution chart, The Klinique Medical Clinic PCL ranks #32 out of 71 companies in the Personal Services industry, placing it in the top 45.1%.
Is The Klinique Medical Clinic PCL's 3-Year EBITDA Growth Rate too high?
The Klinique Medical Clinic PCL's current 3-Year EBITDA Growth Rate of 16.60% is near median its 10-year median of 18.00. Over the past 10 years, this metric has ranged from a low of 16.60 to a high of 29.20. The Personal Services industry median 3-Year EBITDA Growth Rate is 12.10. The Klinique Medical Clinic PCL's value of 16.60% is 37.2% above this industry median. Based on the distribution chart, The Klinique Medical Clinic PCL ranks #32 out of 71 companies in the Personal Services industry, which is above the industry midpoint. Overall, The Klinique Medical Clinic PCL has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Klinique Medical Clinic PCL's 3-Year EBITDA Growth Rate compare to ROL and SCI?
According to the Personal Services industry distribution chart, The Klinique Medical Clinic PCL ranks #32 out of 71 companies for 3-Year EBITDA Growth Rate. This puts The Klinique Medical Clinic PCL in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 12.10. The Klinique Medical Clinic PCL's value of 16.60% is 37.2% above this benchmark. Historically, The Klinique Medical Clinic PCL's own 3-Year EBITDA Growth Rate has ranged from 16.60 to 29.20 over the past decade. While the company's 10-year median is 18.00 vs. the industry median of 12.10, The Klinique Medical Clinic PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Personal Services company?
The median 3-Year EBITDA Growth Rate among Personal Services companies is 12.10, based on 71 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Klinique Medical Clinic PCL's current 3-Year EBITDA Growth Rate of 16.60% is 37.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for The Klinique Medical Clinic PCL and its competitors. For the Personal Services industry, the median 3-Year EBITDA Growth Rate is 12.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Klinique Medical Clinic PCL's current 3-Year EBITDA Growth Rate is 16.60%, which is near median its own 10-year median of 18.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Klinique Medical Clinic PCL stock overvalued right now?
Based on GuruFocus' analysis, The Klinique Medical Clinic PCL (BKK:KLINIQ) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿41.00, compared to a current price of ฿28.50 — trading 30.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.60%, which is near median its 10-year median of 18.00 and 37.2% above the Personal Services industry median of 12.10. The Klinique Medical Clinic PCL's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For The Klinique Medical Clinic PCL (BKK:KLINIQ), the current 3-Year EBITDA Growth Rate is 16.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Klinique Medical Clinic PCL (BKK:KLINIQ) Overvalued in 2026?
Based on GuruFocus' analysis, The Klinique Medical Clinic PCL stock appears to be undervalued.
The current stock price of ฿28.50 is trading 30.5% below its estimated GF Value™ of ฿41.00.
GuruFocus considers The Klinique Medical Clinic PCL to be Significantly Undervalued.
Key valuation signals for BKK:KLINIQ:
3-Year EBITDA Growth Rate: 16.60% (near median its 10-year median of 18.00)
GF Value™: ฿41.00 vs. price of ฿28.50 (30.5% below fair value)
Industry Position: 37.2% above the Personal Services median (#32 of 71)
No single metric tells the full story. See the BKK:KLINIQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Klinique Medical Clinic PCL provides skin care services, beauty, skin care, body contouring, and surgery. including providing holistic care services. The company has a wide range of services and products to meet the needs of customers at all levels, such as facial treatment services, reducing redness, reducing dark spots, laser services for face lifting, face reshaping, skin care, Body shape by removing and dissolving fat, cosmetic surgery, etc. In addition, the company also sells cosmeceuticals. There are various types of products, such as Special Care, Clean & Prepare, Whitening Set, Sun Care, and Antioxidant. The group operates two core business segments: Skin medical services and distribution of cosmetics and medical cosmetics; and Surgery services.
90GF Score
Get the complete analysis for BKK:KLINIQ
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:KLINIQ has been successfully added to your 
